Nkarta (NKTX) Shares Outstanding (Weighted Average) (2019 - 2026)
Nkarta's quarterly Shares Outstanding (Weighted Average) came in at $74.3 million in Q1 2026, little changed year-on-year from $73.9 million in Q1 2025, and up 4.6% quarter-over-quarter from $71.0 million in Q4 2025.
Nkarta has reported Shares Outstanding (Weighted Average) for 8 years, with the latest figure at $74.3 million in Q1 2026.
- For the quarter ending Q1 2026, Shares Outstanding (Weighted Average) changed 0.46% year-over-year to $74.3 million; the trailing twelve-month figure through Mar 2026 stood at $74.3 million (changed 0.46% YoY), and the FY2025 full-year result was $71.0 million, up 4.61% from the prior year.
- Shares Outstanding (Weighted Average) for Q1 2026 stood at $74.3 million, up from $71.0 million in the prior quarter.
- The five-year high for Shares Outstanding (Weighted Average) was $74.3 million in Q1 2026, with the low at $3.0 million in Q1 2024.
- Average Shares Outstanding (Weighted Average) over 5 years is $54.7 million, with a median of $49.0 million recorded in 2023.
- Year-over-year, Shares Outstanding (Weighted Average) sank 93.87% in 2024 and surged 2363.86% in 2025.
- Tracing NKTX's Shares Outstanding (Weighted Average) over 5 years: stood at $43.6 million in 2022, then gained by 12.34% to $49.0 million in 2023, then jumped by 38.46% to $67.9 million in 2024, then grew by 4.61% to $71.0 million in 2025, then increased by 4.6% to $74.3 million in 2026.
- The last three Shares Outstanding (Weighted Average) figures came in at $74.3 million (Q1 2026), $71.0 million (Q4 2025), and $71.0 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares (Weighted Avg.) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 177,333.76 Bn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 185,491.37 Bn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 100.00 Bn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 55.66 Bn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 118.76 Bn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 254.10 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 16.04 Bn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 104.00 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 132.89 Mn |
| 10 | Nkarta | 232.80 Mn | 232.80 Mn | - | 74.26 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 74.26 Mn |
| Dec 31, 2025 | 70.99 Mn |
| Sep 30, 2025 | 70.97 Mn |
| Jun 30, 2025 | 73.95 Mn |
| Mar 31, 2025 | 73.92 Mn |
| Dec 31, 2024 | 67.87 Mn |
| Sep 30, 2024 | 63.88 Mn |
| Jun 30, 2024 | 73.49 Mn |
| Mar 31, 2024 | 3.00 Mn |
| Dec 31, 2023 | 49.01 Mn |
| Sep 30, 2023 | 48.99 Mn |
| Jun 30, 2023 | 48.95 Mn |
| Mar 31, 2023 | 48.92 Mn |
| Dec 31, 2022 | 43.63 Mn |
| Sep 30, 2022 | 41.88 Mn |
| Jun 30, 2022 | 43.84 Mn |
| Mar 31, 2022 | 33.00 Mn |
| Dec 31, 2021 | 32.86 Mn |
| Sep 30, 2021 | 32.90 Mn |
| Jun 30, 2021 | 32.84 Mn |
| Mar 31, 2021 | 32.74 Mn |
| Dec 31, 2020 | 16.92 Mn |
| Sep 30, 2020 | 11.62 Mn |
| Jun 30, 2020 | 1.78 Mn |
| Mar 31, 2020 | 1.61 Mn |
| Dec 31, 2019 | 1.71 Mn |
| Sep 30, 2019 | 1.42 Mn |
| Jun 30, 2019 | 1.70 Mn |